Manitoba man diagnosed with brain cancer says expensive treatment device bought him more time with loved ones

Chico Colosimo, 47, was diagnosed with glioblastoma, an aggressive brain cancer, after a sudden seizure in May 2025. Despite surgery, radiation, and chemotherapy, his condition worsened by December 2025, leaving him unable to speak or move. His wife, Shauna—a radiation therapist—discovered the Optune Gio device, a wearable technology approved by Health Canada in 2022 that uses electric fields to slow cancer cell division. Colosimo began using Optune Gio in late December alongside new medication, leading to gradual improvements. He regained mobility, speech, and quality of life, allowing him to spend time with his 13- and 15-year-old children. Shauna reported reduced tumor size, swelling, and inflammation, calling the treatment a 'blessing.' However, the device costs $28,350 monthly, forcing the family to rely on a GoFundMe campaign raising $160,000, which is now dwindling. British Columbia covers Optune Gio costs, but Manitoba does not. Health Minister Uzoma Asagwara confirmed the device is under review by CancerCare Manitoba, assessing evidence and patient outcomes. Shauna criticized delays, stating glioblastoma patients lack time for prolonged approval processes. The Brain Tumour Foundation of Canada supports nationwide access, arguing patients should not be limited by provincial coverage. Colosimo’s case highlights disparities in treatment access, with his family urging Manitoba to expedite coverage. Without provincial support, patients like him face financial ruin while battling a terminal illness. Shauna emphasized the device’s life-extending benefits, urging the government to prioritize approval for those with limited time.